Matches in SemOpenAlex for { <https://semopenalex.org/work/W2932085132> ?p ?o ?g. }
- W2932085132 endingPage "4349" @default.
- W2932085132 startingPage "4325" @default.
- W2932085132 abstract "5-Lipoxygenase (5-LO)-activating protein (FLAP) inhibitors have proven to attenuate 5-LO pathway activity and leukotriene production in human clinical trials. However, previous clinical candidates have been discontinued and the link between FLAP inhibition and outcome in inflammatory diseases remains to be established. We here describe a novel series of FLAP inhibitors identified from a screen of 10k compounds and the medicinal chemistry strategies undertaken to progress this series. Compound 4i showed good overall properties and a pIC50 hWBfree of 8.1 and an lipophilic ligand efficiency of 5.2. Target engagement for 4i was established in dogs using ex vivo measurement of leukotriene B4 (LTB4) levels in blood with good correlation to in vitro potency. A predicted human dose of 280 mg b.i.d. suggests a wide margin to any identified in vitro off-target effects and sufficient exposure to achieve an 80% reduction of LTB4 levels in humans. Compound 4i is progressed to preclinical in vivo safety studies." @default.
- W2932085132 created "2019-04-11" @default.
- W2932085132 creator A5002088437 @default.
- W2932085132 creator A5004762698 @default.
- W2932085132 creator A5006529178 @default.
- W2932085132 creator A5007029155 @default.
- W2932085132 creator A5010828310 @default.
- W2932085132 creator A5015099141 @default.
- W2932085132 creator A5022430078 @default.
- W2932085132 creator A5022512718 @default.
- W2932085132 creator A5033645248 @default.
- W2932085132 creator A5043511818 @default.
- W2932085132 creator A5065389096 @default.
- W2932085132 creator A5066522294 @default.
- W2932085132 creator A5066992195 @default.
- W2932085132 creator A5069357737 @default.
- W2932085132 creator A5077675752 @default.
- W2932085132 creator A5084268185 @default.
- W2932085132 creator A5084860863 @default.
- W2932085132 date "2019-03-30" @default.
- W2932085132 modified "2023-09-24" @default.
- W2932085132 title "Novel Chemical Series of 5-Lipoxygenase-Activating Protein Inhibitors for Treatment of Coronary Artery Disease" @default.
- W2932085132 cites W1933962987 @default.
- W2932085132 cites W1969293600 @default.
- W2932085132 cites W1971572251 @default.
- W2932085132 cites W1973879072 @default.
- W2932085132 cites W1976186876 @default.
- W2932085132 cites W1980716496 @default.
- W2932085132 cites W1990002508 @default.
- W2932085132 cites W2013191257 @default.
- W2932085132 cites W2062458432 @default.
- W2932085132 cites W2075183706 @default.
- W2932085132 cites W2088755752 @default.
- W2932085132 cites W2101668331 @default.
- W2932085132 cites W2128807065 @default.
- W2932085132 cites W2151223394 @default.
- W2932085132 cites W2153202165 @default.
- W2932085132 cites W2166618785 @default.
- W2932085132 cites W2209117202 @default.
- W2932085132 cites W2323070851 @default.
- W2932085132 cites W2328375070 @default.
- W2932085132 cites W250762689 @default.
- W2932085132 cites W2585194330 @default.
- W2932085132 cites W2626246102 @default.
- W2932085132 cites W2734973925 @default.
- W2932085132 cites W2802677573 @default.
- W2932085132 cites W4230466483 @default.
- W2932085132 cites W4376999360 @default.
- W2932085132 doi "https://doi.org/10.1021/acs.jmedchem.8b02012" @default.
- W2932085132 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30929436" @default.
- W2932085132 hasPublicationYear "2019" @default.
- W2932085132 type Work @default.
- W2932085132 sameAs 2932085132 @default.
- W2932085132 citedByCount "8" @default.
- W2932085132 countsByYear W29320851322020 @default.
- W2932085132 countsByYear W29320851322021 @default.
- W2932085132 countsByYear W29320851322022 @default.
- W2932085132 countsByYear W29320851322023 @default.
- W2932085132 crossrefType "journal-article" @default.
- W2932085132 hasAuthorship W2932085132A5002088437 @default.
- W2932085132 hasAuthorship W2932085132A5004762698 @default.
- W2932085132 hasAuthorship W2932085132A5006529178 @default.
- W2932085132 hasAuthorship W2932085132A5007029155 @default.
- W2932085132 hasAuthorship W2932085132A5010828310 @default.
- W2932085132 hasAuthorship W2932085132A5015099141 @default.
- W2932085132 hasAuthorship W2932085132A5022430078 @default.
- W2932085132 hasAuthorship W2932085132A5022512718 @default.
- W2932085132 hasAuthorship W2932085132A5033645248 @default.
- W2932085132 hasAuthorship W2932085132A5043511818 @default.
- W2932085132 hasAuthorship W2932085132A5065389096 @default.
- W2932085132 hasAuthorship W2932085132A5066522294 @default.
- W2932085132 hasAuthorship W2932085132A5066992195 @default.
- W2932085132 hasAuthorship W2932085132A5069357737 @default.
- W2932085132 hasAuthorship W2932085132A5077675752 @default.
- W2932085132 hasAuthorship W2932085132A5084268185 @default.
- W2932085132 hasAuthorship W2932085132A5084860863 @default.
- W2932085132 hasConcept C114373084 @default.
- W2932085132 hasConcept C116569031 @default.
- W2932085132 hasConcept C126322002 @default.
- W2932085132 hasConcept C150903083 @default.
- W2932085132 hasConcept C170493617 @default.
- W2932085132 hasConcept C181199279 @default.
- W2932085132 hasConcept C185592680 @default.
- W2932085132 hasConcept C202751555 @default.
- W2932085132 hasConcept C204171352 @default.
- W2932085132 hasConcept C207001950 @default.
- W2932085132 hasConcept C26291073 @default.
- W2932085132 hasConcept C2776042228 @default.
- W2932085132 hasConcept C2776452501 @default.
- W2932085132 hasConcept C2776685179 @default.
- W2932085132 hasConcept C2776914184 @default.
- W2932085132 hasConcept C2776980637 @default.
- W2932085132 hasConcept C2778078955 @default.
- W2932085132 hasConcept C2780857362 @default.
- W2932085132 hasConcept C55493867 @default.
- W2932085132 hasConcept C57992300 @default.
- W2932085132 hasConcept C71924100 @default.
- W2932085132 hasConcept C86803240 @default.